An Almost Weekly Summary of Insights, Inspirations, and Thought Provoking Issues
Thanks to all of you, or at least a large majority--our D&D newsletter has reached a milestone. And now I must upgrade to the paid Mail Chimp tier. Because of this epic "things are getting real" status I am working with new formats, original content, and video streams from some of the dozen plus conferences and panel discussions I am invited to attend each year.
While the learning curve is being tamed, I will release some of the new content and topics in a weekend early release here on the blog. Eventually, this will only go to newsletter folks--you should receive something for your loyalty and I hope you find the resource helpful.
If you would like me to feature an article you have written and are shamelessly proud of--simply ask. Speaking of shameless, I stole this format from American Express OPEN.
If you want to subscribe or share the link --> here is the link to the newsletter
Healthcare for people, not consumers...
Like many of you, I will be attending HIMSS17 in a few weeks. It is vital if you are hoping to make sense of changes to health and health IT not only for advancements in improving healthcare but visualizing how the landscape may shift in the new administration. A particular interest of mine and many of my clients is patient engagement. Read More Here
DATA TALKS, MEOPLE PUMBLE
Trends with benefits: improving surveys
The New Year launches new business objectives, insights, and well-intentioned re-alignment for companies to improve strategic offerings. This year, data and how to get some, appears to top many resolutions and skill gap assessments. Before discussions of data analytics can be of benefit, we first need to make sure we are collecting high value information. Read More Here
Why we should listen to Martin Shkreli By Mike Rea
If companies factor in the cost of all of their failures into the price of each new drug, with little incentive to keep costs down, then incentives to fail cautiously are lost. But let’s be honest — we are not trying to limit the price of our new medicines. Companies price their drugs at what someone will pay or, more typically, at what someone can’t refuse to pay. And even if a company limits its yearly increase to 9 percent, what the public hears is that it is raising an old product’s price because it can, not because the drug suddenly became 9 percent more valuable. Read More Here
Meetings and opportunities to connect...
LET'S BUILD A BETTER FOOD POLICY: 2017 Food Tank Summit DC
HIMSS 17 WHERE THE BRIGHTEST MINDS IN HEALTH AND IT MEET
Browse the archive...